LIVN vs. PEN, STVN, IRTC, BLCO, GKOS, TMDX, SLNO, NVST, WRBY, and INSP
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), Warby Parker (WRBY), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.
LivaNova vs. Its Competitors
LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.
Penumbra has a net margin of 11.54% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Penumbra's return on equity.
LivaNova has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
LivaNova has higher earnings, but lower revenue than Penumbra. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
In the previous week, Penumbra had 10 more articles in the media than LivaNova. MarketBeat recorded 19 mentions for Penumbra and 9 mentions for LivaNova. Penumbra's average media sentiment score of 0.95 beat LivaNova's score of 0.17 indicating that Penumbra is being referred to more favorably in the news media.
97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.3% of LivaNova shares are held by company insiders. Comparatively, 4.2% of Penumbra shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
LivaNova presently has a consensus price target of $59.71, suggesting a potential upside of 13.46%. Penumbra has a consensus price target of $302.93, suggesting a potential upside of 18.63%. Given Penumbra's stronger consensus rating and higher probable upside, analysts plainly believe Penumbra is more favorable than LivaNova.
Summary
Penumbra beats LivaNova on 13 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 10/6/2025 by MarketBeat.com Staff